Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $743.4 million.

  • Summit Therapeutics' Shares Outstanding (Weighted Average) rose 230.64% to $743.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $743.4 million, marking a year-over-year increase of 230.64%. This contributed to the annual value of $718.5 million for FY2024, which is 1596.0% up from last year.
  • Summit Therapeutics' Shares Outstanding (Weighted Average) amounted to $743.4 million in Q3 2025, which was up 230.64% from $742.6 million recorded in Q2 2025.
  • Summit Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $743.4 million during Q3 2025, with a 5-year trough of $131.7 million in Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $699.8 million (2023), whereas its average is $571.9 million.
  • In the last 5 years, Summit Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 23399.15% in 2023 and then surged by 146.47% in 2024.
  • Quarter analysis of 5 years shows Summit Therapeutics' Shares Outstanding (Weighted Average) stood at $131.7 million in 2021, then soared by 46.78% to $193.3 million in 2022, then surged by 220.5% to $619.6 million in 2023, then grew by 15.96% to $718.5 million in 2024, then increased by 3.46% to $743.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $743.4 million in Q3 2025, compared to $742.6 million in Q2 2025 and $738.1 million in Q1 2025.